Helix Energy Solutions Group Inc
Change company Symbol lookup
Select an option...
HLX Helix Energy Solutions Group Inc
CTXS Citrix Systems Inc
RAKR Rainmaker Worldwide Inc
CLB Core Laboratories NV
KERN Akerna Corp
T AT&T Inc
YPPN Yappn Corp
RUSHB Rush Enterprises Inc
CMTL Comtech Telecommunications Corp
BMYMP Bristol-Myers Squibb Co
Go

Energy : Energy Equipment & Services | Small Cap Value
Company profile

Helix Energy Solutions Group, Inc. is an international offshore energy services company. The Company provides services to the offshore energy industry, with a focus on well intervention and robotics operations. The Company operates in three segments: Well Intervention, Robotics and Production Facilities. Its Well Intervention segment includes the Company's vessels and equipment used to perform well intervention services primarily in the Gulf of Mexico and North Sea regions. Its Robotics segment includes remotely operated vehicles (ROVs), trenchers and ROVDrills designed to complement offshore construction and well intervention services, and operates chartered ROV support vessels. Its Production Facilities segment includes the Helix Producer I (the HP I), a floating production vessel, the Helix Fast Response System (the HFRS), and its ownership interest in Independence Hub, LLC (Independence Hub).

Premarket

Last Trade
Delayed
$3.01
0.40 (15.33%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$2.61
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
72,284

10-day average volume:
2,419,618
72,284

Boston Pharmaceuticals Licenses NASH Development Candidate from Novartis

8:00 am ET September 1, 2020 (BusinessWire) Print

Boston Pharmaceuticals today announced an agreement with Novartis through which Boston Pharmaceuticals will license worldwide development and commercial rights to the drug candidate BOS-580, for the treatment of Non-Alcoholic Steatohepatitis (NASH).

NASH occurs in 12 percent of patients with nonalcoholic fatty liver disease (NAFLD) when the liver becomes inflamed and fibrotic. A deficiency in fibroblast growth factor 21 (FGF21) favors the development of steatosis, inflammation, hepatocyte damage and fibrosis in the liver of mouse models. BOS-580 is an injectable, genetically engineered variant of human FGF21.

With an optimized, well-tolerated dosing regimen that demonstrates significant hepatic fat reduction and reduced circulating markers of fibrosis, BOS-580 has the potential to be a best-in-class FGF21 agonist.

"As a complex disease with many comorbidities, NASH is an important therapeutic target without effective therapies," said Robert Armstrong, PhD, CEO of Boston Pharmaceuticals. "Novartis has designed the BOS-580 product candidate with a differentiated profile. We are very pleased to build on their high-quality research to develop an innovative potential new therapy for NASH patients."

This is the fourth molecule Boston Pharmaceuticals has licensed from Novartis. In 2018, the company acquired three novel anti-infective programs from the Novartis Infectious Diseases portfolio for the treatment of antibiotic-resistant infections.

About Boston Pharmaceuticals Boston Pharmaceuticals is a clinical stage biopharmaceutical company that leverages an experienced drug development team to advance a portfolio of high value candidates that address important unmet medical needs. The Company partners with innovative biotechnology and pharmaceutical companies to acquire drug development candidates. We employ unencumbered decision making, follow the data and advance only those programs that meet our stringent development hurdles. Following clinical proof of concept, we establish value creating partnerships with the world's leading biotechnology and pharmaceutical companies or advance programs through commercialization. We are continuously seeking new opportunities to leverage our model to create a path to value for our partners and patients. Boston Pharmaceuticals is a portfolio company of Gurnet Point Capital, a Cambridge, MA based private equity firm focused on healthcare investing. For more information, please visit www.bostonpharmaceuticals.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200901005136/en/

SOURCE: Boston Pharmaceuticals">

MacDougall
Kari Watson
kwatson@macbiocom.com 
781-235-3060
comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.